Get Smarter on Biotech in 5 Minutes a Day.
Focused insights — expertly curated, clearly delivered, ready for action.
Get the Daily Brief
What’s in Today’s Brief? (May 17th Preview)
-
Nephrology
RemeGen’s telitacicept cut proteinuria substantially in a prespecified interim look from its Phase 3 TELIGAN trial in IgA nephropathy, according to results reported in NEJM. The therapy—an FC-targeted fusion protein that neutralizes both BAFF and APRIL—delivered a −58.9% change from baseline in the 24-hour urinary protein-to-creatinine ratio at week 39 versus −8.8% with placebo. In the same interim analysis, estimated glomerular filtration rate was broadly similar between groups, with −1.0% on telitacicept versus −7.7% on placebo, based on confidence intervals provided in the report. Adverse events were more frequent with telitacicept (89.3% vs 78.6%), though serious adverse events were less common (2.5% vs 8.2%). With 318 patients randomized (159 per arm), the study reached its primary endpoint with a relative difference of −55.0% (95% CI, −61.3 to −47.6; P<0.001). The trial is registered as NCT05799287 and supported by RemeGen.
-
Oncology diagnostics and liquid biopsy
Researchers presented new data at ESTRO 2026 on a blood-based circulating tumor DNA approach for tailoring treatment in oligometastatic breast cancer. The work uses ctDNA detected in plasma as a biomarker to inform therapeutic decisions, positioning the assay as a potential decision layer before or around radiotherapy. The report ties the ctDNA readout to treatment selection for patients whose disease has begun to spread but remains limited—an area where clinicians increasingly want earlier signals of biology and response. Details on performance metrics were not provided in the excerpt, but the presentation frames ctDNA as a practical, minimally invasive tool to guide therapy in advanced settings where treatment selection is challenging.
-
Oncology—radiotherapy in early metastatic disease
A targeted stereotactic body radiotherapy strategy showed potential to extend control in early-stage breast cancer spread, according to findings presented at the ESTRO Congress 2026. The approach targets oligometastatic lesions—patients whose cancer has started to metastasize but remains limited in burden—with the aim of improving progression-free outcomes. The presentation highlights a renewed focus on radiotherapy as more than palliative care, emphasizing precision targeting to keep disease in check while limiting exposure to surrounding tissue. Clinical impact will hinge on how progression-free survival and safety compare with existing standards in the patient population studied. The excerpt does not provide trial design specifics, but the congress venue and the focus on oligometastatic disease mark a notable development for radiation oncology pipelines.
-
Oncology—radiotherapy de-escalation in prostate cancer
A study presented at ESTRO 2026 suggests prostate cancer radiotherapy could be delivered in only two sessions over eight days without adding side effects versus the conventional five-fraction schedule. The findings, reported in Stockholm, frame a potential de-escalation pathway focused on maintaining safety while reducing treatment time. For patients and providers, fewer visits can reduce burden and improve throughput in radiation oncology services. For industry stakeholders, regimen simplification can influence payer coverage discussions and operational models for departments delivering radiotherapy. The excerpt does not include absolute efficacy numbers or subgroup breakdowns, but the equal safety premise is the central takeaway from the presentation.
-
Regulatory and approvals—oncology
FDA approval updates for fam-trastuzumab deruxtecan were reported, indicating the agency cleared two separate new indications for the antibody-drug conjugate. The update was circulated via a submission reference rather than a full release in the provided excerpt. For biotech and pharma decision-makers, incremental label expansion can affect standard-of-care positioning, sequencing with other HER2-directed therapies, and demand forecasting across oncology practices. Key details on indications and trial bases were not included in the excerpt, but the regulatory action itself signals continued movement of the ADC’s clinical footprint.
...and 5 more selected Biotech stories in today’s full edition — or archive.
Why BioBriefs?
- Expertly curated. We scan 200+ sources daily to deliver only what matters.
- Smart context. Each brief explains why it matters and who it impacts.
- Made for pros. Trusted by founders, scientists, investors, and strategists.
Who Reads BioBriefs?
- Biotech founders & execs
- R&D and Clinical leads
- Life sciences investors
- Regulators and BD pros
- Translational scientists and tech scouts
Stay sharp. Be first to what’s next.
About BioBriefs
We’re a team of biotech analysts, technical writers, and founders who know what it’s like to scan 40 tabs and still miss what matters. BioBriefs was built to solve that. We track the signals, condense the insights, and get them to you before your day starts.